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Strengths and limitations of this study
 ► The first randomised controlled trial to compare 
three- dimensional (3D) total- body photography 
(TBP) to standard- of- care for people who are at high 
risk of melanoma.
 ► Large sample size, recruited from research volun-
teer registry and dermatologist referrals with a pro-
jected high retention rate.
 ► Collection of longitudinal data from government 
health repositories will allow a relatively complete, 
rich data set on healthcare use and costs relevant 
to melanoma risk.
 ► Study will evaluate feasibility of using 3D TBP for 
telediagnosis.
 ► Limited outcomes assessment, with absence of 
gold- standard mortality as an endpoint.
AbStrACt
Introduction Melanoma is Australia’s fourth most 
common cancer. Early detection is fundamental in 
maximising health outcomes and minimising treatment 
costs. To date, population- based screening programmes 
have not been justified in health economic studies. 
However, a skin surveillance approach targeting high- risk 
individuals could improve the cost- benefit ratio.
Methods and analysis This paper describes a 2- 
year longitudinal randomised controlled trial (RCT) to 
compare routine clinical care (control) with an intensive 
skin surveillance programme (intervention) consisting 
of novel three- dimensional (3D) total- body photography 
(TBP), sequential digital dermoscopy and melanoma- 
risk stratification, in a high- risk melanoma cohort. 
Primary outcomes will evaluate clinical, economic and 
consumer impact of the intervention. Clinical outcomes 
will evaluate differences in the rate of lesion excisions/
biopsies per person, benign to malignant ratio for 
excisions and thickness of melanomas diagnosed. 
A health economic analysis using government data 
repositories will capture healthcare utilisation and costs 
relating to skin surveillance. Consumer questionnaires 
will examine intervention acceptability, the psychological 
impact, and attitudes towards melanoma risk and sun 
protective behaviour. Secondary outcomes include the 
development of a holistic risk algorithm incorporating 
clinical, phenotypic and genetic factors to facilitate 
the identification of those most likely to benefit from 
this surveillance approach. Furthermore, the feasibility 
of integrating the intervention with teledermatology 
to enhance specialist care in remote locations will be 
evaluated. This will be the first RCT to compare a targeted 
surveillance programme utilising new 3D TBP technology 
against current routine clinical care for individuals at high 
risk of melanoma.
Ethics and dissemination This study has received 
Human Research Ethics Committee (HREC) approval 
from both Metro South Health HREC (HREC/17/
QPAH/816) and The University of Queensland HREC 
(2018000074).
trial registration number ANZCTR12618000267257; 
Pre- results.
IntroduCtIon
Australia, with a population of only 25 million 
residents, has one of the highest rates of cuta-
neous melanoma incidence and mortality in 
the world, with over 13 000 new cases diag-
nosed in 2016, and over 1700 deaths.1 In 
2014, the costs of advanced melanoma were 
estimated to be $A422 million nationally of 
which 39% was attributable to direct health-
care costs.2 Early detection of melanoma is 
preferred because more advanced stage mela-
nomas have poorer patient outcomes and 
are costly to manage.3–5 While population- 
based screening is not warranted, identifying 
people at high risk of melanoma could enable 
targeted screening, and be the most effective 
way of improving early detection. Extensive 
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research efforts have been undertaken to improve strat-
egies for identifying and following those at greatest risk.6 
However, there is currently no consensus on the best risk 
assessment or surveillance strategies. As a result, screening 
recommendations vary and are inconsistently applied.7
Current approaches for identifying and screening those 
at greatest risk are imperfect.8 Risk prediction tools have 
been developed, and involve weighting a subset of risk 
factors including phenotypic features, personal history 
and, more rarely, genetic test results. The most important 
markers of individual melanoma risk include: CDKN2A 
germline mutation, having >100 naevi, >5 atypical naevi, 
fair hair, eye and skin colour, a strong family history or 
a personal history of melanoma.6 9 10 Within Australia, 
dermatologists typically adhere to The Cancer Council 
Australia’s guidelines, that recommend high- risk individ-
uals undergo clinical skin examinations every 6 months 
using total- body photography (TBP) in combination with 
sequential digital dermoscopy imaging (SDDI).11 12
TBP provides a comparative record of the skin surface 
assisting in identification of new lesions and to an extent, 
changes of existing naevi. Dermoscopy enables the visu-
alisation of the surface morphology of pigmented skin 
lesions and reveals colours and structures that normally 
are not visible to the naked eye. Dermoscopy has consis-
tently been shown to improve the diagnostic accuracy of 
melanomas,13 and when used across visits it is particularly 
useful for detection of incipient melanomas, which lack 
typical dermoscopy features.14 This ‘two step’ process 
involving both TBP and dermoscopy for skin surveillance 
was initially described in 200215 and has been repeatedly 
shown to be associated with a lower benign to malignant 
excision ratio and decreased Breslow thickness of subse-
quently diagnosed melanomas.4 13 16 17 More recently, 
surveillance of clinical patients at high risk of mela-
noma has demonstrated efficacy and cost- effectiveness. A 
large 10- year, retrospective review of a high- risk clinic in 
Sydney, Australia reported that patients were diagnosed 
with thinner melanomas, and underwent fewer exci-
sion compared with standard care.4 A review of previous 
studies exploring targeted screening for melanoma using 
visual skin inspection reported mixed findings for cost- 
effectiveness depending on the baseline level of risk for 
the targeted population.18
Surveillance strategies have evolved significantly over 
the past decade. One of the most promising approaches 
involves automated three- dimensional (3D) imaging of 
subjects, allowing objective documentation of all existing 
lesions and monitoring changes over time. The VECTRA 
WB360 system described previously19 20 allows fast 3D 
TBP and construction of a patient avatar, along with inte-
grated dermoscopy. Consumer feedback indicates high 
acceptability and confidence in the technology for skin 
monitoring, and importantly, whole body imaging may 
reduce melanoma- related anxiety.19 The advances in 
total- body imaging in recent years were unprecedented, 
and now enable high resolution 3D imaging in minutes. 
The impact of these changes on health economic models 
of high- risk screening warrants investigation. It is the 
objective of the current study to examine the use of 3D 
imaging technology for targeted surveillance for individ-
uals at high risk to melanoma.
The geographical distribution of the population in 
Australia creates additional challenges to equitable health 
service delivery.21 Melanoma patients in rural areas of 
Australia are often disadvantaged with inequitable access 
to dermatological care and are reported to suffer 20% 
increased melanoma- related mortality compared with 
urban areas.21 Already now, rural physicians are using 
teledermatology to obtain second opinions on suspicious 
lesions from specialist dermatologists.22 Incorporating 
3D TBP into a teledermatology service could facilitate 
remote full body skin examination by teledermatologists 
reflecting the service level that urban patients can access. 
The current study will evaluate the feasibility of using a 
telehealth network for transmission of 3D TBP–SDDI 
images, and the concordance of diagnostic decisions 
between in- person skin examinations and remote teleder-
matologist review.
This study will recruit individuals that are at high risk 
of developing cutaneous melanoma to participate in a 
randomised trial comparing combined TBP and SDDI 
surveillance approach (3D TBP–SDDI), with routine 
clinical care. TBP and SDDI reportedly improve earlier 
detection rates13 23; however, the effect of 3D TBP is 
unknown. The feasibility of extending its use through a 
telehealth network will be explored. An evaluation of effi-
cacy, costs and consumer acceptability of the technology 
will determine long- term sustainability. Furthermore, a 
standardised, holistic approach to risk stratification for 
melanoma will be developed, optimising the identifica-
tion of those who would most benefit from this high- risk 
surveillance programme. This study is an integral step in 
guiding change in the way high- risk individuals may be 
managed in Australia.
objECtIvES
Primary objectives
 ► Compare clinical outcomes of the 3D TBP–SDDI 
approach with routine clinical care, including 
numbers of excisions or biopsies and histopatholog-
ical findings.
 ► Compare health economic outcomes of the 3D TBP–
SDDI approach with routine clinical care.
 ► Evaluate consumer acceptance of the intervention, 
psychological well- being, health behaviour and beliefs 
regarding sun protection and melanoma.
Secondary objectives
 ► Assess feasibility of telehealth to deliver remotely 
captured 3D TBP–SDDI for teledermatologist review.
 ► Evaluate the degree of concordance between teleder-
matologist and in- person examination in terms of 
clinical assessment and management decisions.
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 ► Identify rare and deleterious gene variants associated 
with melanoma risk.
 ► Refine a risk stratification model that combines 
medical history, family history, phenotypic risk factors 
and genetic results to produce a melanoma- risk score.
MEthodS And AnAlySIS
Study design and setting
A two- arm, single- site, parallel randomised controlled 
trial (RCT) will recruit 330 participants, with a 50:50 allo-
cation ratio between intervention and control groups. 
Study visits commenced in April 2018, and are expected 
to be completed by August 2021. The study site will be the 
Clinical Research Facility of the Translational Research 
Institute at the Princess Alexandra Hospital, Brisbane. 
The majority of study participants reside in South- East 
Queensland, Australia.
Participant and public involvement
Prior to applying for funding, we have conducted clin-
ical research recruiting both average risk and high- risk 
members of the public regarding skin surveillance since 
2010, and have used questionnaires for participant feed-
back regarding skin cancer prevention which has contrib-
uted to the current study design. Since 2016, we have held 
biannual consumer forums to inform the public and our 
study participants of our research progress, and to give 
consumers the opportunities to discuss their priorities 
and concerns regarding skin cancer prevention with our 
group.
Eligibility criteria
Individuals that are at high risk of developing a primary 
or subsequent primary melanoma will be invited to 
participate. High risk will be defined as having one of the 
following:
 ► At least one melanoma (including in situ) diagnosed 
before the age of 40 years.
 ► Two or more melanomas (including in situ) diag-
nosed before the age of 65 years.
 ► A strong family history (2+ first- degree relatives) and/
or known pathogenic genetic mutation and/or a diag-
nosis of dysplastic naevus syndrome.
recruitment
Participants will be recruited from a registry of research 
volunteers with the University of Queensland, Derma-
tology Research Centre, and by referrals from derma-
tologists and medical practitioners from South- East 
Queensland, over a 12–18- month period. Potential partic-
ipants will be emailed a short description of the study and 
a copy of the participant information and consent form, 
followed by a phone call approximately 2 weeks thereafter.
randomisation and blinding
Once consented at the initial baseline visit, participants 
will be randomised to either the intervention or control 
group with simple random sampling using the rando-
misation function in Research Electronic Data Capture 
(REDCap). REDCap is a secure, online study database 
software developed by Vanderbilt University, and admin-
istrated by The Queensland Clinical Trials and Biostatis-
tics Centre at the School of Public Health, The University 
of Queensland. Simple randomisation method is selected 
as it is an agnostic approach which is straightforward 
to implement. It is acknowledged that this approach is 
vulnerable to random sampling errors; however, we will 
account for this in our secondary analysis. An online 
random number generator24 will create an allocation 
sequence table which will be uploaded to REDCap. Trial 
staff conducting patient visits will be blinded to the next 
allocation sequence. Due to the nature of the interven-
tion once participants are randomised, allocation is 
unblinded.
To address the teledermatology objectives, a subset of 
participants will be evaluated two ways. First by 3D TBP–
SDDI and a face- to- face dermatologist, and second their 
images alone will be independently evaluated by another 
dermatologist.
Intervention
Participants randomised to the intervention group 
will receive clinical skin examinations, every 6 months 
for 2 years, supported by the 3D TBP imaging system 
(VECTRA WB360, serial number WB00009, Canfield 
Scientific, Parsippany, New Jersey, USA). The VECTRA 
imaging system consists of a framework of 92 cameras, 
which simultaneously capture images of the participant 
holding one anatomical pose, to construct a 3D avatar. An 
attached dermoscopic camera (EOS Rebel T6i) enables 
imaging of individual naevi including anatomical local-
isation on the 3D avatar. Clinical skin examinations are 
performed at the time of imaging by dermatologically- 
trained medical practitioners, and images are reviewed 
and discussed fortnightly with an accredited derma-
tologist, simulating a teledermatology consultation to 
assess 3D TBP avatars and corresponding dermoscopic 
images. Suspicious lesions will be discussed with the study 
participant by phone, and subsequently referred to their 
treating physician. Participants will be asked to continue 
attending their regular skin examination appointments.
Control
Participants randomised to the control group will be 
asked to continue attending their regular skin examina-
tion appointments (which may include two- dimensional 
(2D) TBP), and to complete six monthly questionnaires 
(as described in table 1 and figure 1). At the end of the 
study, all control participants will be offered a clinical skin 
examination including 3D TBP imaging.
Participant timeline
Participants in both groups will be evaluated over a 
2- year period from baseline, with the intervention group 
attending visits at baseline, 6, 12, 18 and 24 months. 
The control group will attend the clinic in person at 
baseline and at 24 months, and will complete an online 
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Table 1 Primary outcomes and methods assessments
Outcome category Themes evaluated Data source Time points
Clinical Number and thickness of 
melanomas (including in 
situ) found.
Clinical records and pathology reports. 0, 6, 12, 18 and 24 months
Skin excisions/biopsies 
and the histopathological 
categorisations.
Economic Participant healthcare 
services utilisation relating 
to skin surveillance and 
management.
Participant claims through the Medicare 
Benefits Schedule and Pharmaceutical 
Benefits Scheme.
One- off extraction capturing 
the entire study period of 0–24 
months
Queensland Hospital Admitted Patient 
Data Collection database, the Healthcare 
Purchasing and System Performance 
data and the Health Service Funding 
Models.
Consumer Satisfaction and 
acceptability
Self- administered, validated 
questionnaire27 adapted from the 
Technology Acceptance Model.28 29
Additional questions will capture 
satisfaction with travel, waiting times, 
appointment length, convenience 
and perceived financial value of the 
surveillance programme.
Recruitment and retention will contribute 
to analysis.
0 and 24 months
Health behaviours Self- administered, validated 
questionnaire adapted from QSkin study 
to capture sun protective behaviours and 
relevant demographics.30
0, 6, 12, 18 and 24 months
Psychological well- being Euro- QoL- 5D,31 to capture quality 
of life index for the health economic 
assessment.
0, 6, 12, 18 and 24 months
Health beliefs The validated Health Beliefs Survey32 
33 to evaluate knowledge, perceived 
severity of melanoma, perceived 
personal risk and perceived worthiness 
of surveillance programmes.
0, 6, 12, 18 and 24 months
questionnaire at months 6, 12 and 18. Refer to figure 1 
for an overview of participant timeline and assessments.
Primary outcomes
The primary outcome for this study is the number of 
excisions. The other main outcomes are defined in three 
categories, including clinical, economic and consumer 
outcomes. The assessments of these outcomes are 
described in table 1.
Secondary outcomes
There are three secondary outcomes: the feasibility of 
viewing 3D TBP–SDDI images remotely using the tele-
health network; the efficacy of performing skin exam-
inations using 3D TBP–SDDI images using telehealth 
services and lastly the identification of genetic mutations 
and their utility in melanoma- risk stratification. The 
assessments of these outcomes are described in table 2.
data collection and management
Baseline questionnaire and clinical data will be entered 
into the REDCap database. 3D TBP–SDDI images will be 
captured using the VECTRA imaging system and inte-
grated software. Pathology reports will be requested from 
the Queensland Cancer Registry and medical records. 
One- off extractions of claims and health service data will 
occur at the end of follow- up from the Medicare Benefits 
Schedule (MBS) and Pharmaceutical Benefits Scheme 
(PBS), the Queensland Hospital Admitted Patient Data 
Collection database, the Healthcare Purchasing and 
System Performance data, and the Hospital and Health 
Service Funding Models. By linking data, the whole 
journey of healthcare service contacts and patient skin 
cancer outcomes will be captured, to allow an estimate 
of related costs of skin cancers. Costs will be analysed 
from the health provider (government) perspective. 
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Figure 1 Overview of participant timeline and assessments.
Intervention resources will be compiled and monitored 
by the project manager.
Saliva samples and subsequent sequencing results will 
be coded and linked using a re- identifiable ‘study ID’. 
Data linking identifying information and study ID will 
be stored in a password- controlled database, on a secure 
server, accessible to a limited subset of the study team to 
ensure privacy.
The REDCap management system, the VECTRA 
images and all remaining electronic data will be stored 
under The University of Queensland Research Data 
Management system on a secured network. Identifiers 
are removed from all participant data and replaced with a 
unique study ID to further protect privacy. Regular quality 
assurance checks of image data and REDCap entries will 
be conducted.
data monitoring
The study team determined that an independent data 
monitoring committee was not required as the risk to 
study participants was low, mainly relating to privacy 
and the possibility of unnecessary excision or biopsies. 
Privacy risks are mitigated as discussed above. An ‘issues 
register’ will be kept to record technical problems that 
occur during trial visits. Interviews with key stakeholders 
will identify problematic procedures. Any concerns with 
data quality or issues recorded will be discussed at regular 
team meetings. The study team will perform regular data 
monitoring and quality assurance tasks internally, and any 
protocol deviations or adverse events will be reported to 
the ethics committee.
StAtIStICAl MEthodS
Sample size
The study aims to recruit 330 high- risk participants over a 
12–18- month period, to be powered to compare excision 
rates between groups. This sample size is based on previ-
ously reported difference in excision rates in a high- risk 
sample, between those monitored by TBP (mean=0.81, 
SD=0.75) and a standard care group (mean=2.55, 
SD=2.01).4 The definition of high risk is broader in this 
study, and approximately one- third of participants are 
likely to be already monitored using TBP, therefore the 
difference between routine clinical care and monitoring 
with 3D TBP is likely to be smaller. Given this, the study 
was powered to observe a 50% smaller difference in exci-
sion rates than observed previously,4 including an increase 
in SD of 50% within each group (mean intervention 0.81 
(SD=1.13), mean control 1.68 (SD=3.02)). Given these 
estimates, with a power of 90% and a significance level of 
5%, 153 participants will be required for each arm of the 
trial. Allowing for participant withdrawal, we will aim to 
recruit a total 330 participants.
baseline demographic
Descriptive statistics will be used to summarise demo-
graphic and clinical characteristics for both the control 
and intervention groups. χ2 tests will be used to estimate 
difference in proportions of categorical variables between 
the two groups, and t- tests will be used for continuous 
variables. Non- parametric equivalents will be used if the 
assumptions of the parametric tests are violated. Results 
will be considered statistically significant if p<0.05.
Clinical outcomes
A non- parametric Mann- Whitney test will be used to assess 
the clinical primary outcome to test if there is a difference 
in mean annual rate of lesion excisions/biopsies between 
the intervention and control groups, given the primary 
outcome is based on counts and therefore unlikely to 
follow a normal distribution. The primary outcome will 
be analysed as intention to treat, with a per protocol 
analysis as a secondary outcome. This outcome will also 
be re- evaluated on a subset excluding those from both 
the intervention and control groups who are receiving 
2D TBP. The benign to malignant ratio for excisions of 
pigmented lesions and non- melanoma skin cancers will 
be calculated for both groups. χ2 test or fisher’s exact 
test (as appropriate) will be used to compare the differ-
ence in proportions of pathology confirmed melanoma, 
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Table 2 Secondary outcomes and methods assessments
Outcome category Factors evaluated Data source Time points
Feasibility of telehealth 
approach
Technical feasibility of 
telehealth network for remote 
dermatological review of 
3D TBP–SDDI images, and 
interoperability with hospital 
image repositories and 
integrated electronic medical 
records
 ► Investigate subsystems for image acquisition, 
storage and display by measuring network 
throughput (bandwidth) and latency between 
subsystems.
 ► Measure data volume and transmission time 
per 3D TBP–SDDI examination.
 ► Assess the compression ratio of transmitted 
image files necessary to achieve adequate 
functionality.
 ► Evaluate success of transmission and 
integrity of data.
24 months
Accuracy of telehealth skin 
examinations
Safety and accuracy of 
teledermatology review of 3D 
TBP–SDDI images
 ► Review the concordance between provisional 
diagnosis and clinical management decisions 
of the teledermatologist to the gold standard 
of in- person dermatological assessment.
 ► Assess comparative diagnostic accuracy 
between in- person clinical diagnosis, 
teledermatological diagnosis and 
histopathological diagnoses.
0–24 months
Melanoma- risk stratification 
in a high- risk population
Genetic results  ► Saliva samples collected using Oragene 
DNA self- collection kit. Methods for sample 
processing described previously.27
Baseline
 ► Whole exome sequencing or Sanger 
sequencing used to identify rare, pathogenic, 
germline variants in known melanoma genes.
 ► Common variants associated with melanoma 
risk will be genotyped using Illumina 
CoreExomev24 chip array.
12–24 
months
Sun behaviour  ► Self- administered, previously validated 
sun behaviour questionnaire to record 
sun protective behaviour, sun exposure, 
sunburn history, personal and family skin 
cancer history, and relevant demographic 
information.27 30
Baseline
Deep phenotyping  ► Documentation of eye, hair and skin colour.
 ► Spectrophotometer readings for skin colour 
on the right arm including the proximal 
anterior bicep, proximal anterior forearm 
and proximal posterior forearm, using 
Spectrometer CM- 600d (Konica Minolta, 
Osaka, Japan).
 ► Digital photographs of participant’s irises 
using a Nikon D3400 digital single- lens reflex 
camera (Nikon, Tokyo, Japan).
 ► Freckling on the face, dorsum of right hand 
and shoulders are rated 0–4 (none, mild, 
moderate, severe) to produce an overall 
freckling score.
Baseline
3D, three dimensional; SDDI, sequential digital dermoscopy imaging; TBP, total- body photography.
melanoma in situ, basal cell carcinoma and squamous cell 
carcinoma diagnosed between the two groups with diag-
nosis. Logistic regression analyses will be used to inves-
tigate the relationship between baseline demographic 
and phenotypic information, and past melanoma history. 
A subgroup analysis of participants diagnosed with 
melanoma excluding in situ and melanoma including 
in situ will investigate the differences in staging, Breslow 
thickness and body site and other parameters of interest, 
between the two groups, using linear, logistic and gener-
alised regression models as appropriate. As above, results 
will be considered statistically significant if p<0.05. As 
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primary outcome data will be collected through Medicare 
information consented to at baseline, there will be no or 
very minimal missing data. Therefore assuming the data 
are missing at random, we will remove participants with 
no outcome data from that analysis.
Economic outcomes
The economic analysis will assess the resource and cost 
differences between arms rather than a full economic 
evaluation due to the relatively short follow- up and 
small sample with which to detect health outcomes such 
as skin cancers. Data from Medicare and Queensland 
Health sources will be linked and aggregated for each 
patient covering the surveillance period of the study. 
Skin cancer related resource use will be identified and 
coded according to ICD-10 (International Classification 
of Diseases), procedure and MBS/PBS items. Cost data 
are typically skewed so generalised linear models will be 
used with a gamma family and log link (if appropriate) to 
assess differences between the intervention and control 
groups. Non- parametric bootstrapping methods will also 
be applied for verification of differences in costs between 
groups. Subgroup cost analyses of hospital versus out- 
of- hospital, melanoma stage, age, phenotypes or other 
patient characteristics will be explored.
telehealth review outcomes
The main telehealth outcome is the level of agreement in 
clinical decision between the teledermatologist and the 
dermatologist carrying out an in- person skin examina-
tion assessment. Four decision outcomes will be consid-
ered: No action (no suspicious lesion), follow- up in 3–6 
months, excision of lesion(s) and treatment of lesion. 
Weighted Cohen’s kappa coefficient will be calculated 
to measure agreement across the four categories using R 
package irr.25 A kappa between 0.6 and 0.79 will indicate 
substantial agreement, while a kappa of greater than 0.8 
will indicate almost perfect agreement.26
Melanoma-risk score development
Multivariable logistic regression will be used to assess what 
combinations of genetic, phenotypic and demographic 
risk factors are associates with an increased odds of mela-
noma within a high- risk population. Variables with p<0.2 
in univariate regression will be included in the model, and 
backwards stepwise regression will be used, with variables 
in the model remaining statistically significant at the 5% 
level. Validation of the resulting risk stratification algo-
rithms will be performed on larger collaborative cohorts.
Consumer perspectives
Data will be collected to determine the acceptability and 
feasibility of 3D imaging and any potential barriers and 
facilitators to implementation and adoption. This will 
include information related to convenience, comfort, 
and reasons for participant retention/loss and data on 
quality of life and fear of recurrence.
Questionnaire data will be prepared according to each 
scale’s manual and standard procedures.27–33 Total and 
subscale scores will be computed and tested for normality. 
If normally distributed, parametric tests will be used, 
otherwise non- parametric analytic procedures will be 
used as described above to assess differences between the 
two groups in the consumer self- reported outcomes.
EthICS And dISSEMInAtIon
The protocol has been prepared in concordance with 
the Standard Protocol Items Recommendations for Inter-
ventional Trials (SPIRIT) statement.34 Following national 
guidelines, if genetic sequencing reveals a high pene-
trance pathogenic mutation, clinical genetic testing will 
be offered to the participant. A reimbursement of $A20 
per visit will be paid to participants to assist in covering 
travel and/or parking costs. Study results will be dissem-
inated through peer- reviewed publications, conferences 
and non- peer reviewed media outlets.
dISCuSSIon
This will be the first RCT to assess the feasibility, efficacy 
and cost- effectiveness of combining 3D TBP, with SDDI 
for clinical skin examinations of individuals at high risk 
to melanoma in Australia. Consumer perceptions of the 
technology and its clinical utility will also be assessed. 
This study will enable us to determine whether excision 
rates and stage of melanoma detection are affected by 
the inclusion of 3D TBP–SDDI in a surveillance protocol. 
Exploring the societal and personal costs of the interven-
tion will be invaluable in determining the feasibility of 
incorporating this technology in routine clinical care for 
this high- risk cohort. The study will determine whether 
remote administration of 3D TBP, with SDDI combined 
with teledermatologist evaluation will affect clinical 
management. For greater public benefit in the longer 
term, it is critical to be able to accurately identify high- risk 
individuals who might benefit from this more intensive 
surveillance approach and, therefore, this study aims to 
develop a holistic risk stratification algorithm.
Australia currently has three national population- based 
screening programmes for early detection of breast, 
cervical and bowel cancers. However, there is no similar 
programme for skin cancer, despite melanoma being 
Australia’s fourth most common cancer.10 The number 
needed to screen (NNS) in the Australian general public 
to save one life from melanoma has been estimated at 
25 000.35 Therefore, population- based screening for 
melanoma may not be justified. However, by focusing on 
a high- risk population the probability of detecting a mela-
noma increases and the NNS decreases. Furthermore, 
the incorporation of TBP- SDDI enables a ‘watch and 
wait’ approach which would reduce the number needed 
to treat based on the benign to malignant excision ratio, 
resulting in health cost savings.11 Criteria for an effective 
screening programme, outlined by the Australian Insti-
tute for Health and Welfare,36 stipulate that: the disease 
must be highly prevalent; the natural course of the disease 
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is well understood including a recognisable latent or early 
symptomatic stage where disease can be detected; there is 
available treatment which is effective and well accepted; 
the disease must cause considerable costs, both fiscally 
and clinically; and lastly, the screening programme must 
be cost effective. With the criteria in mind, the current 
protocol is intended to build the evidence for a future 
targeted surveillance programme for melanoma detec-
tion in high- risk individuals in Australia, including solu-
tions for geographical challenges. Economic evaluation 
of resource use and associated costs collected through 
linkage of clinical and administrative healthcare data 
sources will capture the whole journey of health service 
contacts and outcomes, to accurately estimate the related 
costs of screening and skin cancers within this high- risk 
population.
ConCluSIon
This protocol will provide evidence as to whether pursuing 
the incorporation of 3D TBP–SDDI into a surveillance 
programme for high- risk individuals can be cost effective 
and provide superior clinical outcomes over the current 
routine clinical care. Secondary outcomes will drive solu-
tions in defining the population which would maximally 
benefit from this programme, and determine the accept-
ability of this surveillance method. Furthermore, the study 
will determine if the 3D TBP–SDDI technology is suitable 
for review through telehealth services, supporting solu-
tions for outreach to remote regions of the country.
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